(EMAILWIRE.COM, August 07, 2019 ) PEGylated proteins products include consumables and services mainly used for cancer treatment, hepatitis, chronic kidney diseases, haemophilia, multiple sclerosis, and gastrointestinal disorders.

The global PEGylated proteins market is expected to reach USD 1,137.8 Million by 2021 from USD 690.6 Million in 2016, at a CAGR of 10.5% from 2016 to 2021. Increase in R&D spending of pharmaceutical & biotechnology companies, growth in biologics sector, high prevalence of lifestyle disease, increasing adoption of protein based drugs over non-protein based drugs are the primary growth drivers for this market during the forecast period (2016–2021). However, drug failure and recalls may hinder the growth of this market.

The global PEGylated proteins market is segmented on the basis of products, protein type, application, and end-user. On the basis of product, the market is segmented into consumables and services.

Of these, the consumables product segment accounted for the largest share of the global PEGylated proteins market in 2016. The large share of this segment can primarily be attributed to the increasing adoption of kit-based PEGylation products.

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=19242378

On the basis of end-user, the market is segmented into pharmaceutical & biotechnology companies, CROs, and academic research institutes. Of these, the pharmaceutical & biotechnology companies end-user segment accounted for the largest share of the global PEGylated proteins market in 2016, owing to increased R&D spending by pharmaceutical and biotechnology companies.

A combination of bottom-up and top-down approaches was used to calculate the market sizes and growth rates of the global PEGylated proteins market and its subsegments. All percentage shares, splits, and breakdowns were determined using secondary sources and verified through primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. Primary interviews with key opinion leaders were also used to determine the percentage shares of each subsegment and the relative differences in growth rates.

Geographic analysis reveals that North America accounted for the largest share of the PEGylation of Proteins market in 2016. Growth in this market can be attributed to the increasing adoption of biologics drugs such as monoclonal antibodies, erythropoietin and interferon for the treatment of chronic diseases, increasing government funding and grants for research activities, and increase in R&D spending for drug discovery at early stages.

The global PEGylated proteins market was dominated by Merck Millipore (U.S.), Thermo Fisher Scientific, Inc. (U.S.), and NOF Corporation (Japan) in 2016. With a broad product portfolio and collaborations and agreements as a key strategy, Merck Millipore held the leadership position in the global PEGylated proteins market in 2016. Merck Millipore signed an agreement with Y-mAbs Therapeutics, Inc. based in New York, U.S. Over the past three years, the company adopted the strategy of agreement & collaboration and acquisition to maintain its leadership position in the global PEGylated proteins market.

The other key players in this market include JenKem Technology USA, Inc. (U.S.), Creative PEGworks (U.S), Celares GmbH (Germany), Quanta BioDesign, Ltd. (U.S.), Biomatrik, Inc, (China), Iris Biotech GmbH (Germany), Laysan Bio, Ltd. (U.S.).

Read More@
https://www.marketsandmarkets.com/PressReleases/pegylated-protein.asp

The global PEGylated proteins market is highly evolved, with multiple product segments. An analysis of the market developments between 2013 and 2016 revealed that agreement & collaboration and product launch was the most important growth strategy employed by market leaders in this period. This strategy was adopted by all the players in this market.

The other important growth strategy adopted by players in this market is acquisitions and product upgradation. This strategy was adopted by the market players to enhance their product portfolio and geographic presence. These strategies were adopted by major the players in this market such as Merck Millipore (U.S.), Thermo Fisher Scientific, Inc. (U.S.), NOF Corporation (Japan) between 2013 and 2015.

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
sales@marketsandmarkets.com